Two-year results of a phase III three-part study showed that the IL-6 receptor inhibitor Actemra was highly effective in the treatment of severe systemic JIA, and that responses were still high at the five-year mark among patients who continued on the standard regimen of Actemra. Actemra is the first biologic to be licensed for use in systemic JIA.

Click here fore more.